153 related articles for article (PubMed ID: 36102989)
1. Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team.
Fan C; Kim A; Li S; Naidoo J; Cappelli LC; Brahmer JR; Anders RA; Kim AK
J Cancer Res Clin Oncol; 2023 Feb; 149(2):877-883. PubMed ID: 36102989
[TBL] [Abstract][Full Text] [Related]
2. Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy.
Zhang Q; Chen L; Guo X; Shen L; Huang Y; Chen Y; Zhang N; Ge N; Gao H; Zhang W; Hou Y; Ji Y
Ann Diagn Pathol; 2024 Feb; 68():152225. PubMed ID: 38016303
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers.
Yamamoto A; Yano Y; Ueda Y; Yasutomi E; Hatazawa Y; Hayashi H; Yoshida R; Asaji N; Shiomi Y; Tobimatsu K; Sakai A; Kodama Y
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1747-1756. PubMed ID: 33222015
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
7. The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management.
Lasagna A; Sacchi P
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398187
[TBL] [Abstract][Full Text] [Related]
8. Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.
Smith MK; Chan Y; Suo AE; Shaheen AA; Congly SE; Tandon P; Bhanji RA; Wells MM; Cheng T; Ma C
J Can Assoc Gastroenterol; 2022 Feb; 5(1):39-47. PubMed ID: 35118226
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil.
Sato K; Inoue J; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Ouchi K; Masamune A
Clin J Gastroenterol; 2023 Oct; 16(5):720-725. PubMed ID: 37480423
[TBL] [Abstract][Full Text] [Related]
10. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
11. [Pathological features of immune-mediated hepatitis due to immune checkpoint inhibitors and anti-angiogenesis targeted therapy].
Zhang QY; Chen LL; Gao F; Sujie A; Hou YY; Huang XW; Huang C; Sun HC; Zhou J; Ji Y
Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):329-335. PubMed ID: 32268669
[No Abstract] [Full Text] [Related]
12. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury.
Zen Y; Yeh MM
Mod Pathol; 2018 Jun; 31(6):965-973. PubMed ID: 29403081
[TBL] [Abstract][Full Text] [Related]
16. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives.
Liu Z; Zhu Y; Xie H; Zou Z
Front Pharmacol; 2022; 13():1077468. PubMed ID: 36699050
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
18. A novel pathologic marker, indoleamine 2,3-dioxygenase 1, for the cholangiopathy of immune checkpoint inhibitors-induced immune mediated hepatotoxicity as adverse events and the prediction of additional ursodeoxycholic acid treatment.
Yoshimura K; Tamano Y; Nguyen Canh H; Zihan L; Le Thanh D; Sato Y; Terashima T; Shimoda S; Harada K
Med Mol Morphol; 2023 Jun; 56(2):106-115. PubMed ID: 36599971
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors-Induced Hepatitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():159-164. PubMed ID: 30539511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]